Dublin - Research and Markets (http://www.researchandmarkets.com/research/d27f58de/which_strategies_c) has announced the addition of GlobalData's new report "Which Strategies can Big Pharmaceutical Companies Use to Manage the Impact of Patent Protection Loss?" to their offering.
Which Strategies can Big Pharmaceutical Companies Use to Manage the Impact of Patent Protection Loss?
The report is an essential source of information and analysis on the patent protection strategies by Big Pharma along with the case studies. The report provides insights on the companies as well as products that were launched to minimise the impact of loss of patent protection. Most importantly, the report provides valuable insights on the analytical and quantitative aspects of patent protection-off impact.
Reasons to Buy:
- Enhance your decision making capabilities in minimising your going to face patent protection-off.
- Develop strategies to launch new products that can minimise your company to loose revenues by products loosing patent protection.
- Adopt and follow the strategies that companies have implimented to maximise their revenues
- Identify how companies could see new market opportunies from existing products
- Develop your strategies to identify the right target for product acquisition or marketing agreements
- Develop and enrich your product pipeline that can create additionl opportunities from mutiple indications
- How companies did mimise the loss of revenues via patent protection-off ? - Identify, understand and capitalize
Key Topics Covered:
1 Tables & Figures
2 Summary
3 Which Strategies can Big Pharmaceutical Companies Use to Manage the Impact of Patent Protection Loss?
3.1 Introduction
3.2 Loss of Patent Protection Causes Serious Impact on Cash Flows
3.2.1 Prozac and Zocor - Classic Examples of the Impact of Patent Loss
3.3 Evergreening: A Tough Challenge Necessitates Strategy - Lessons from the Past
3.3.1 Pediatric Exclusivity - the immediate option for a company
3.3.2 Chiral Switches - the Most Preferred by the Industry
3.3.3 Launching Combination Products
3.3.4 Rx to OTC switch
3.3.5 Other strategies
4 Appendix
For more information visit http://www.researchandmarkets.com/research/d27f58de/which_strategies_c
Source: GlobalData